These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 17439507)

  • 1. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin.
    Casellas F; Borruel N; Torrejón A; Varela E; Antolin M; Guarner F; Malagelada JR
    Aliment Pharmacol Ther; 2007 May; 25(9):1061-7. PubMed ID: 17439507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
    Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
    Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
    D'Haens G; Hommes D; Engels L; Baert F; van der Waaij L; Connor P; Ramage J; Dewit O; Palmen M; Stephenson D; Joseph R
    Aliment Pharmacol Ther; 2006 Oct; 24(7):1087-97. PubMed ID: 16984503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additional oligofructose/inulin does not increase faecal bifidobacteria in critically ill patients receiving enteral nutrition: a randomised controlled trial.
    Majid HA; Cole J; Emery PW; Whelan K
    Clin Nutr; 2014 Dec; 33(6):966-72. PubMed ID: 24290345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis.
    Johnson MW; Maestranzi S; Duffy AM; Dewar DH; Forbes A; Bjarnason I; Sherwood RA; Ciclitira P; Nicholls JR
    Eur J Gastroenterol Hepatol; 2008 Mar; 20(3):174-9. PubMed ID: 18301296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
    Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
    Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic and inflammatory faecal markers in collagenous colitis.
    Wildt S; Nordgaard-Lassen I; Bendtsen F; Rumessen JJ
    Eur J Gastroenterol Hepatol; 2007 Jul; 19(7):567-74. PubMed ID: 17556903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.
    Miner PB; Wedel MK; Xia S; Baker BF
    Aliment Pharmacol Ther; 2006 May; 23(10):1403-13. PubMed ID: 16669955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-digestible oligosaccharides and calcium absorption in girls with adequate calcium intakes.
    Griffin IJ; Davila PM; Abrams SA
    Br J Nutr; 2002 May; 87 Suppl 2():S187-91. PubMed ID: 12088517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
    Sandborn WJ; Regula J; Feagan BG; Belousova E; Jojic N; Lukas M; Yacyshyn B; Krzeski P; Yeh CH; Messer CA; Hanauer SB
    Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
    Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
    Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined butyric acid/mesalazine treatment in ulcerative colitis with mild-moderate activity. Results of a multicentre pilot study.
    Assisi RF;
    Minerva Gastroenterol Dietol; 2008 Sep; 54(3):231-8. PubMed ID: 18614971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prebiotic fructans have greater impact on luminal microbiology and CD3+ T cells in healthy siblings than patients with Crohn's disease: A pilot study investigating the potential for primary prevention of inflammatory bowel disease.
    Hedin CR; McCarthy NE; Louis P; Farquharson FM; McCartney S; Stagg AJ; Lindsay JO; Whelan K
    Clin Nutr; 2021 Aug; 40(8):5009-5019. PubMed ID: 34364241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study.
    Biancone L; Gionchetti P; Blanco Gdel V; Orlando A; Annese V; Papi C; Sostegni R; D'Incà R; Petruzziello C; Casa A; Sica G; Calabrese E; Campieri M; Pallone F
    Dig Liver Dis; 2007 Apr; 39(4):329-37. PubMed ID: 17347061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis.
    Kato K; Mizuno S; Umesaki Y; Ishii Y; Sugitani M; Imaoka A; Otsuka M; Hasunuma O; Kurihara R; Iwasaki A; Arakawa Y
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1133-41. PubMed ID: 15569116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Scherl EJ; Pruitt R; Gordon GL; Lamet M; Shaw A; Huang S; Mareya S; Forbes WP
    Am J Gastroenterol; 2009 Jun; 104(6):1452-9. PubMed ID: 19491859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
    Miele E; Pascarella F; Giannetti E; Quaglietta L; Baldassano RN; Staiano A
    Am J Gastroenterol; 2009 Feb; 104(2):437-43. PubMed ID: 19174792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic aspirin therapy does not increase faecal calprotectin concentrations.
    Montalto M; Curigliano V; Santoro L; Lombardi M; Covino M; Cammarota G; Dalvai S; D'Onofrio F; Gasbarrini A; Gasbarrini G
    Eur J Gastroenterol Hepatol; 2006 Sep; 18(9):965-7. PubMed ID: 16894309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of oligofructose-enriched inulin supplementation on gut microbiota, nutritional status and gastrointestinal symptoms in paediatric coeliac disease patients on a gluten-free diet: study protocol for a pilot randomized controlled trial.
    Krupa-Kozak U; Drabińska N; Jarocka-Cyrta E
    Nutr J; 2017 Aug; 16(1):47. PubMed ID: 28830428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis.
    van Deventer SJ; Wedel MK; Baker BF; Xia S; Chuang E; Miner PB
    Aliment Pharmacol Ther; 2006 May; 23(10):1415-25. PubMed ID: 16669956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.